Mirum Pharmaceuticals Grants 15,820 Stock Options and 7,840 RSUs to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Source: Businesswire
Updated: 23 hour ago0mins
- Incentive Program Implementation: On December 10, 2025, Mirum's 2020 Inducement Plan granted 15,820 non-qualified stock options and 7,840 RSUs to eight new employees, aimed at attracting and retaining talent to enhance the company's competitive edge in the rare disease sector.
- Options Details: Each stock option has an exercise price of $64.67, based on the closing price on the grant date, and will vest over four years with 25% vesting in the first year and the remainder monthly, ensuring a long-term service relationship with the company.
- RSU Vesting Arrangement: The RSUs will vest over three years with 33% vesting each year, designed to incentivize ongoing contributions from new employees, thereby enhancing team stability and execution capabilities.
- Strategic Company Positioning: By focusing on the development of rare disease medications, this incentive measure further solidifies Mirum's leadership in the global rare disease market, driving the research and commercialization of innovative drugs.
MIRM.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on MIRM
Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is 88.11 USD with a low forecast of 77.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 64.670
Low
77.00
Averages
88.11
High
95.00
Current: 64.670
Low
77.00
Averages
88.11
High
95.00
Leerink
Outperform
maintain
$90 -> $100
2025-12-10
New
Reason
Leerink
Price Target
$90 -> $100
2025-12-10
New
maintain
Outperform
Reason
Leerink raised the firm's price target on Mirum Pharmaceuticals to $100 from $90 and keeps an Outperform rating on the shares. The firm updated its Mirum model for the Bluejay acquisition terms and concurrent Private Investment in Public Equity, both expected to close in Q1. Meanwhile, clinical development and commercialization of brelovitug is expected to require about $250M over the next two years, and Mirum will pay up to $200M in tiered sales milestones, the analyst tells investors in a research note. Following encouraging Phase 2 ddata for brelovitug for the treatment of chronic hepatitis delta, Phase 3 interim data is expected in 2Q26 and topline results in 2H26, the analyst adds.
Baird
Outperform
maintain
$80 -> $88
2025-12-09
New
Reason
Baird
Price Target
$80 -> $88
2025-12-09
New
maintain
Outperform
Reason
Baird raised the firm's price target on Mirum Pharmaceuticals to $88 from $80 and keeps an Outperform rating on the shares. The firm updated its model following its Blujay acquisition which brings in an attractive opportunity in HDV.
Morgan Stanley
Michael Ulz
Overweight
maintain
$81 -> $95
2025-12-09
New
Reason
Morgan Stanley
Michael Ulz
Price Target
$81 -> $95
2025-12-09
New
maintain
Overweight
Reason
Morgan Stanley analyst Michael Ulz raised the firm's price target on Mirum Pharmaceuticals to $95 from $81 and keeps an Overweight rating on the shares. The acquisition of Bluejay adds brelovitug, which has demonstrated "promising activity and tolerability" in hepatitis delta virus and expands rare liver disease pipeline while providing synergies, the analyst tells investors.
Cantor Fitzgerald
Overweight
maintain
$95 -> $130
2025-12-08
New
Reason
Cantor Fitzgerald
Price Target
$95 -> $130
2025-12-08
New
maintain
Overweight
Reason
Cantor Fitzgerald raised the firm's price target on Mirum Pharmaceuticals to $130 from $95 and keeps an Overweight rating on the shares. Mirum's proposed acquisition of Bluejay Therapeutics for $250M in cash, $300M in stock, and $200M in tiered milestone payments is a "steal," the analyst tells investors in a research note.
See All Ratings
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What were the details of Michael G Grey's share sale in 2025?
How does the acquisition of Bluejay Therapeutics enhance Mirum's portfolio?
What impact will the Phase 3 brelovitug results have on Mirum's stock price?
Will the $200 million private placement be sufficient for commercialization efforts?